过去十年非核苷类逆转录酶抑制剂使用变化未改变抗逆转录病毒治疗病毒学失败HIV感染者的NNRTI耐药生态
该研究在一家学术中心分析了2014-2023年接受抗逆转录病毒治疗的HIV感染者中NNRTI使用情况及病毒学失败时的NNRTI耐药谱。结果显示NNRTI使用频率保持高位,依非韦伦、奈韦拉平、依曲韦林使用下降,利匹韦林和多拉韦林上升;依非韦伦、奈韦拉平、利匹韦林耐药率仍高于15%,依曲韦林和多拉韦林耐药率较低。结论认为NNRTI使用变化未改变NNRTI耐药生态。
要点
- NNRTI使用频率在43.5%(n=1782/4094)至39.9%(n=1758/4421)间波动。
- 依非韦伦、奈韦拉平和利匹韦林耐药率仍高于15%。
- 依曲韦林和多拉韦林耐药率较低。
核心结论
- NNRTI类药物仍被广泛使用,该类药物使用变化未改变研究期间接受抗逆转录病毒治疗且病毒学失败的HIV感染者的NNRTI耐药生态。
研究设计与样本
- 在一家学术中心分析2014-2023年接受抗逆转录病毒治疗的HIV感染者的NNRTI使用情况及病毒学失败时的NNRTI耐药谱,使用ANRS-MIE算法v33分析HIV逆转录酶序列的耐药突变谱。
主要发现
- NNRTI使用频率在43.5%(n=1782/4094)至39.9%(n=1758/4421)之间波动。
- 依非韦伦使用从10.8%降至1.5%,奈韦拉平从7.0%降至1.2%,依曲韦林从11.0%降至1.1%。
- 利匹韦林使用从14.7%升至26.3%,多拉韦林自2018年可用,2023年升至9.7%。
- 依曲韦林(P=0.033)和利匹韦林(P<0.001)使用趋势具有统计学显著性。
- 依非韦伦耐药率从17.3%降至16.6%,奈韦拉平从16.9%降至15.4%,利匹韦林从17.6%降至16.1%,均保持在15%以上,反映三者间显著交叉耐药。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine how non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance profiles have changed over the last decade in people living with HIV (PLWHIV) experiencing virological failure on all antiretroviral treatments, including different NNRTIs. MATERIALS AND METHODS: We analysed the use of the different NNRTIs in PLWHIV treated with antiretroviral drugs at an academic centre and the HIV NNRTI resistance profiles observed in cases of virological failure over the last 10 years (2014-23). We used the latest ANRS-MIE algorithm (v33; https://hivfrenchresistance.org/) to analyse the resistance mutation profiles of the HIV reverse transcriptase sequences. RESULTS: During this period, the frequency of NNRTI use remained high, fluctuating slightly between 43.5% (n = 1782/4094) and 39.9% (n = 1758/4421). The use of efavirenz (10.8%-1.5%), nevirapine (7.0%-1.2%), and etravirine (11.0%-1.1%) decreased, whereas the use of rilpivirine (14.7%-26.3%) and doravirine (available from 2018, rising to 9.7% in 2023) increased. These trends were statistically significant for etravirine (P = 0.033) and rilpivirine (P < 0.001). Resistance rates for efavirenz, nevirapine and rilpivirine remained above 15% (efavirenz: 17.3%-16.6%, nevirapine: 16.9%-15.4% and rilpivirine: 17.6%-16.1%). This reflects significant cross-resistance between these three NNRTIs. By contrast, resistance rates were lower for etravirine (7.8%-6.0%) and doravirine (4.9%-4.6%), probably due to differences in their resistance profiles and higher genetic barriers to resistance. CONCLUSIONS: The NNRTI class of antiretroviral drugs remains widely used. Changes in the usage of drugs from this class have not altered the ecology of NNRTI resistance in antiretroviral drug-treated PLWHIV with virological failure during the studied period.
引用
- Soulie C, Agher R, Fauchois A, et al. Changes in NNRTI use have not altered the ecology of NNRTI resistance over the last 10 years in people with HIV experiencing virological failure on antiretroviral drugs. J Antimicrob Chemother. 2025. PMID: 39704180. doi:10.1093/jac/dkae458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。